ISPOR Europe Program. New Perspectives for Improving 21st Century Health Systems

Transcription

1 ISPOR Europe 2018 Register by 25 September 2018 and SAVE! The Leading European Conference for Health Economics and Outcomes Research November 2018 Centre de Convenciones Internacional de Barcelona Barcelona, Spain Program New Perspectives for Improving 21st Century Health Systems Join colleagues to discuss the latest trends in health economics and outcomes research (HEOR) and help shape the future of HEOR. ISPOR is the leading scientific and educational organization for HEOR and its use in healthcare decision making. Learn new methods and novel applications in the conduct and use of HEOR. Engage with recognized global experts in the field. Network with colleagues, collaborators, and clients. Share your research and ideas with other ISPOR members in an open and neutral environment. Stay current on emerging trends in healthcare. Advance your career through active participation (eg, attend an ISPOR Short Course or a New Professional event). Why Attend an ISPOR Conference? ISPOR Europe 2018 will provide a forum for discussion and dissemination of HEOR information. The conference is a great opportunity to present your work, collaborate and network with colleagues in the field, and hear about innovative research methods and new health policy developments. Reflecting on revolutionary transformations affecting today s healthcare, ISPOR Barcelona will address fair and sustainable pricing issues, health technology assessment particularly as it relates to the foundation of comparative clinical effectiveness, and policy and clinical decision making in budget constrained environments while exploring the theme New Perspectives for Improving 21st Century Health Systems. Who Attends? The ISPOR sphere of influence engages global leaders in the international HEOR community, including policy makers, regulators, researchers, academicians, health technology developers, payers, decision makers, and patient groups. 18% increase in submissions! #ISPORBarcelona Trending topics: Real-World Data/Evidence Digital Health and Artificial Intelligence Clinical Outcomes Assessment Patient Preferences Economic and Survival Modeling Economic Evaluation Use of Health Policy in Decision Making Health Technology Assessment Personalized Medicine Medical Devices and Diagnostics Oncology Medication Adherence and Compliance Patient Engagement Patient Reported Outcomes Value of a Cure Specialized Treatment Areas including Nutrition, Rare Diseases, and Regenerative Medicine New European Union Legislations Drug Disinvestment Drug Pricing Expert Elicitation QALYs Universal Health Coverage Patient Privacy Missing Data and Statistical Methods Communication of CostEffectiveness Estimands Indirect Treatment Comparisons Biosimilars

2 Make the most of ISPOR Europe 2018! PROGRAM ISPOR Barcelona 2018 features nearly 2500 presentations! The program offers scientific topics of interest, for example: modeling, patient reported outcomes (PROs), health technology assessment (HTA), and more, at multiple session times and in a variety of presentation formats. Pre-Conference Short Courses are training courses off ered across 7 HEOR key topic areas. The skill level ranges from introductory to advanced, and continuing education credits are available. Separate registration is required. Plenary Sessions feature thought-provoking discussions on challenging topics related to healthcare policy, the application of HEOR in healthcare decision making, or methodology. Spotlight Sessions highlight timely topics in HEOR and promote areas of innovation of interest to the ISPOR community. Issue Panels (IP) introduce debate with multistakeholder perspectives on new or controversial issues in HEOR. Workshops (W) discuss new and innovative applications in the conduct and use of HEOR or the latest on real-world data, clinical-, economic-, or patient-reportedoutcomes, patient-preferences, and healthcare policy. ISPOR Forums (F) are presented by ISPOR Groups on country/regional health policy, scientific research/ initiatives, good practices for outcomes research, research tools, or publications. Podium Presentations (P) sessions consist of four 15-minute outcomes research presentations on a single topic. Poster Presentations Sessions contain approximately 500 research posters per session arranged by disease, topic, or health care intervention with a scheduled author discussion hour. Symposia are sponsored presentations related to ISPOR s mission. The sponsor organization selects a subject of interest to delegates and arranges suitable speakers. Open Meetings leaders of ISPOR s SIGs, interact with other participants interested in the same topics and provide input on the direction of projects for ISPOR groups. These groups develop valuable manuscripts, webinars, and tools to advance the field of HEOR. Open to all attendees. Thank you to the following ISPOR 2018 Supporters and Sponsors: (Sponsors as of August 2018) Platinum Level: Analytica Laser/BaseCase Gold Level: HealthCore Silver Level: Covance Evidera IBM Watson Health Ingress Health Bronze Level: SIRIUS Market Access Interested in becoming an Event Sponsor? Visit Event/Sponsors/2018Barcelona for available sponsorships. NETWORKING Connect with ISPOR members, colleagues, collaborators, and clients. Meet with experts, clients, and other attendees. Schedule meetings via the ISPOR Europe 2018 mobile app and web platform (available approximately 1 month prior to the conference). Join your ISPOR colleagues at the Social Event on Tuesday evening. Separate registration required. Engage in session discussions with colleagues during the morning and afternoon coffee breaks or during lunch in the Poster and Exhibit Hall. Explore the Exhibit Hall and find products and services that meet your needs. Network with student members worldwide at roundtables, showcases, receptions, and more. ISPOR GROUPS Collaborate with members of your ISPOR groups. ISPOR Regional Groups (Chapters, Networks, and Consortia): Join the educational, research, and policy-related activities of these groups and meet other HEOR professionals from your region of the world. ISPOR Scientific and Health Policy Groups (Task Forces, Special Interest Groups, and Council Working Groups): Collaborate with members of these groups and participate in the development of ISPOR knowledge products, such as ISPOR Good Practices for Outcomes Research Task Force Reports, manuscripts for Value in Health, and online tools used by decision makers and researchers around the world. New Professionals: We encourage our New Professional members to attend the New Professional Event, Career Advice Across The Globe. The event is designed to provide both New Professional and soon-tograduate Student members with the opportunity to hear first-hand experiences from established ISPOR members around the world on various career related topics. This will be the second time this event is held in Europe with the first being last year's installment "The Art of Getting Published." For more information about New Professional member benefits please visit member-groups/students/ Students: Network with international student members! Join us at the Student Research Showcase, Student & New Professional Mixer, Career Advice Across The Globe, and the Student Luncheon (if you are a member of an ISPOR student chapter)! To form a Student Chapter at your University, studentnetwork@ispor.org. We also invite you to follow to learn more about the ISPOR Student Network and benefits. 2 #ISPORBarcelona

3 Plenary Sessions Featured at ISPOR Europe 2018 FIRST PLENARY SESSION: Monday, 12 November from 9:15-10:45 Joint Assessment of Relative Effectiveness: Trick or Treat for Decision Makers in EU Member States Evidence-based health policy and decision making necessitates more and better clinical evidence on relative efficacy, effectiveness, and therapeutic benefits of new or existing health technologies. However, requirements to develop evidence on added therapeutic value as well as the requirements on the transparency of assessment process for consequent decision making are uneven and frequently not aligned in the European Union (EU) member states. This leads to a line of challenges ranging from questions on the quality of assessments produced by various health technology assessment (HTA) bodies, to problems with patient access to innovative technologies and jeopardized sustainability of the healthcare systems of the EU member states. The European Commission s draft regulation on HTA that proposes a Europe-wide introduction of a joint clinical assessment (and other measures) is intended to address some of the above challenges. Can joint clinical assessment be a way forward to ensure more and better clinical evidence to improve decision making on availability and provision of new or existing health technologies? Will it make a big difference for the availability and quality of the clinical evidence? What are the opportunities to strengthen HTA methodologies and processes of the EU member states? A panel of stakeholders from the European HTA bodies, European institutions, industry, patients, and payers have been invited to address these and other timely questions as well as discuss risks and benefits of the joint clinical assessments to move beyond the status quo in HTA processes in Europe. SECOND PLENARY SESSION: Tuesday, 13 November from 9:00-10:30 Pharmaceutical Pricing: The Many Faces of Fairness In 2017, the World Health Organization (WHO) convened the first Fair Pricing Forum to focus global attention on the apparent perversity of high prices that restrict access to essential patented medicines and the unpredictability of low prices that drive shortages in the generics sector. Stakeholders discussed perspectives on the current pricing systems and identified a need for a fairer system that is sustainable for health systems, investors, and the pharmaceutical industry. While the definition of what is fair and whether it is feasible to achieve are two separate but related constructs, the focus of the plenary is on defining fair in the context of pharmaceutical pricing. Speakers will also explore whether it is possible (or necessary) to come to a shared understanding of fairness. Could a renewed focus on the shared objectives of achieving universal health coverage, sustainable development goals, and access to medicines provide the catalyst for identifying non-regulatory strategies to address the current inequities and provide much needed access? Or is further regulation required? THIRD PLENARY SESSION: Wednesday, 14 November from 10:30-11:45 Budget Impact and Expenditure Caps: Potential or Pitfall? Many health systems in the European Union are tempted to control the budget impacts of health policies by implementing financial caps and linking pharmaceutical expenditure to gross domestic product. Proponents of budget-capping policies consider them to be promising in terms of cost-containment, affordability, and predictability and believe these approaches are needed to prevent impinging on other social policy goals. Critics of these policies suggest that, while they may appear to contribute to financial control in the short term, it is doubtful that this type of macroeconomic course of action contributes to efficiency, the diffusion of innovation, or the provision of appropriate incentives for competition. An important question is whether a budget-capping strategy encourages or undermines the achievement of better health outcomes, in both the short term and the long term, in a way that is consistent with overall societal goals. Should the financial vehicles of the Economic Ministries be the principal driver of the economics of health policy? Or should the driving and the road map for better health of the population be in the hands of the highest government authority with the accompanying support of health economics? How can budget-controlling approaches be designed to best foster continued innovation? CONFERENCE PROGRAM COMMITTEE ISPOR thanks the Conference Program Committee for its contributions in developing the scientific community s leading HEOR program. Program Committee Co-Chairs Sarah Garner, PhD, World Health Organization (WHO), Geneva, Switzerland Zoltan Kalo, PhD, Professor of Health Economics, Eötvös Loránd University, Budapest, Hungary Guillem López-Casasnovas, PhD, Universitat Pompeu Fabra, Barcelona, Spain Research Review Committee Co-Chairs Murtuza Bharmal, PhD, Merck KGaA, Darmstadt, Germany Margreet G. Franken, PhD, Erasmus University, Rotterdam, The Netherlands Robert Hettle, MMAth, AstraZeneca, Cambridge, United Kingdom Andrea Manca, MSc, PhD, University of York, Heslington, York, United Kingdom Issue Panel Review Committee Co-Chairs René Allard, PhD, Grünenthal GmbH, Aachen, Germany Luciana Ballini, BSc, MSc, Azienda USL-IRCCS Reggio Emilia Regional Agency for Health, Emilia Romagna, Italy Jamie O Hara, HCD Economics, Brussels, Belgium Workshop Review Committee Co-Chairs Martin Scott, MSc, Numerus Ltd., Tubingen, Germany Paul O Donohoe, MS, BS, Medidata Solutions, London, United Kingdom Carme Pinyol, MD, PhD, MSc, Pierre Fabre, Barcelona, Spain 3

4 Pre-Conference Short Course Program Learn. Apply. Advance. Attend any session, including one of our 6 NEW courses! The ISPOR HEOR Short Course Program, offered in conjunction with ISPOR conferences around the world as a series of 4- and 8-hour training courses, is designed to enhance your knowledge in 7 key topic areas ( tracks ) related to HEOR. Short courses (many with hands-on training opportunities) range from introductory to advanced and are taught by leading experts in the field. Separate registration is required for Short Courses. Economic Methods Introduction to Health Economics Evaluations Statistical Methods for Health Economics and Outcomes Research NEW! Alternative Economic Assessment for Expressing Healthcare Value and Informing Resource Allocation Decisions Cost-Effectiveness Analysis Alongside Clinical Trials Transferability and Relevance of Cost- Effectiveness Data between Countries Budget Impact Analysis I: A 6-Step Approach Budget Impact Analysis II: Applications & Design Issues Modeling Methods Introduction to Modeling Register Now Development of Conceptual Models NEW! Introduction to Constrained Optimization Methods for Health Care Research Pharmacoeconomic Modeling - Applications Bayesian Analysis - Overview and Applications Using DICE Simulation for Health Economic Analyses Understanding Survival Modeling with Application to HTA NEW! Value of Information (VOI) Analysis Observational Data Methods Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources Use of Propensity Scores in Observational Studies of Treatment Effects Use of Instrumental Variables in Observational Studies of Treatment Effects Advanced Methods for Addressing Selection Bias in Real-World Effectiveness and Cost- Effectiveness Studies Adjusting for Time-Dependent Confounding and Treatment Switching Bias in Observational Studies and Clinical Trials: Purpose, Methods, Good Practices and Acceptance in HTA Outcomes Research Methods NEW! Tools for Reproducible Real-World Data Analysis Meta-Analysis & Systematic Literature Review Network Meta-Analysis in Relative Effectiveness Research Patient-Preference Methods Conjoint Analysis - Theory & Methods Collecting Health-State Utility Estimates for Economic Models in Clinical Studies Mapping to Estimate Utility Values from Non- Preference Based Outcome Measures Patient-Reported Outcomes Methods Introduction to Patient-Reported Outcomes Assessment Use of Pharmacoeconomic/Economic/ Outcomes Research Information Elements of Pharmaceutical/Biotech Pricing Introduction to Health Technology Assessment NEW! Analysis of Longitudinal Data: Fixed and Random Effects Models Using Multi-Criteria Decision Analysis in Health Care Decision Making: Approaches & Applications Risk Sharing / Performance-Based Arrangements for Drugs and Other Medical Products Introduction to the Economic Analysis of Diagnostics Risk-Sharing/Performance-Based Arrangements in Central & Eastern Europe: Implementation of Managed Entry Agreements Reimbursement Systems for Pharmaceuticals in Europe NEW! Multi-Criteria Support Systems for Group Decision Making Select courses require use of your personal laptop. Short Courses are offered Saturday, 10 November and Sunday, 11 November: SHORT COURSE FEES ALL-DAY COURSES Through 25 September 2018 Standard: 790 ($977) Clinical/Government/Academia: 590 ($729) Full-Time Students/Patient Representatives: 200 ($247) After 25 September 2018 Standard: 890 ($1,100) Clinical/Government/Academia: 690 ($853) Full-Time Students/Patient Representatives: 250 ($309) HALF-DAY COURSES Through 25 September 2018 Standard: 395 ($488) Clinical/Government/Academia: 295 ($365) Full-Time Students/Patient Representatives: 100 ($124) After 25 September 2018 Standard: 445 ($550) Clinical/Government/Academia: 345 ($426) Full-Time Students/Patient Representatives: 125 ($155) CONFERENCE ENHANCEMENT FEES Short Course Continuing Education Accreditation (CPE & CME): 115 ($142) SEPARATE SHORT COURSE REGISTRATION IS REQUIRED See program for the Short Course schedule, descriptions, and to register. 4 #ISPORBarcelona

5 Conference Program ISPOR Europe 2018 features 3 thought-provoking plenary sessions and more than 2500 presentations in the form of workshops, issue panels, forums, symposia, podium presentations, and poster presentations on innovative research methods, health policy development using outcomes research, patient preferences, real-world data, and clinical-, economic-, and patient-reported outcomes. Program subject to change. Saturday 10 November 8:00-17:00 PRE-CONFERENCE HEOR SHORT COURSES (separate registration required) Sunday 11 November 8:00-17:00 PRE-CONFERENCE SHORT COURSES (separate registration required) 17:30-18:30 EDUCATIONAL SYMPOSIUM How Should We Measure Quality of Life Impact in Rare Disease: Recent Learnings in Spinal Muscular Atrophy (Sponsored by Biogen) 18:45-19:45 EDUCATIONAL SYMPOSIUM Automation In Public Health Evaluations and Decision Making: How Far Can It Go? How Far Should It Go? (Sponsored by Analytica Laser, a Certara Company) Monday 12 November 7:30-8:30 EDUCATIONAL SYMPOSIUM Indication Based Pricing; Who Wins, Who Loses, and Where Next? (Sponsored by AstraZeneca) 8:30-19:45 EXHIBIT AND POSTER HALL HOURS 8:45-13:45 RESEARCH POSTER SESSION 1 8:45-10:45 WELCOME & FIRST PLENARY SESSION Joint Assessment of Relative Effectiveness: Trick or Treat for Decision Makers in EU Member States 10:45-11:45 BREAK, EXHIBITS & POSTERS 11:15-12:15 BREAKOUT SESSION 1 IP1: Global Biopharmaceutical Innovation Too Much, Too Little, or Both? IP2: Can Patient Involvement In Early Dialogues (Early Scientific Advice) Increase The Value Of The Advice Given? IP3: Will Machines Soon Make Health Economists Obsolete? W1: Roadblocks and Resolutions: Development of Pro Instruments for Multinational Trials W2: Challenges In The Use Of Real-World Evidence For Pharmacoeconomic Modeling P1: Methods in Cancer Studies P2: Issues and Trends in Health Technology Assessment 12:15-14:15 LUNCH, EXHIBITS & POSTERS 12:45-13:45 ISPOR STUDENT RESEARCH SHOWCASE 12:45-13:45 EDUCATIONAL SYMPOSIUM Raising Organizational Fluency in Real World Evidence Through Interactive Learning Techniques (Sponsored by Syneos Health) 12:45-13:45 POSTER AUTHOR DISCUSSION HOUR 14:15-15:15 SPOTLIGHT SESSION 1 IP4: Healthcare X.0: Digital Technologies and Creation of Value IP5: Prove It with PROS W3: Adjusting For Postrandomization Confounding and Switching In Phase III and Pragmatic Trials to Get the Estimands Right: Needs, Methods, Sub-Optimal Use, and Acceptance in HTA 15:15-15:45 BREAK & EXHIBITS 15:45-16:45 BREAKOUT SESSION 2 IP6: Do Novel Value Measures Have a Place in European HTA? IP7: Changing Paradigm in The Evaluation of the Value Of Medical Devices: What Must Stakeholders Expect in the New Decade? IP8: HTA Value Based Pricing Versus Who Fair Pricing: Which Delivers Universal Health Coverage? W4: Towards Personalization: How Can Advanced Quantitative Methods Help Regulators, Reimbursement Agencies and Clinicians Make Better Decisions for Individual Patients? W5: Application of Gamification in Healthcare and Outcomes Measurement: Improving Treatment Compliance and Research Engagement P3: Cost-Effectiveness Studies P4: Conceptual Papers 15:45-19:15 RESEARCH POSTER SESSION 2 17:00-18:00 BREAKOUT SESSION 3 IP9: Back to the Future: Should We Live in a Post-QALY World? IP10: Embracing the Societal Perspective for HTAs: Will it Become the New Standard for Reference Case? IP11: The Evolving EU Policy Landscape: Are We on the Right Path to Improve Clinical and Economic Outcomes Research of Medical Devices? W6: Economic Model Choice, Validation, and Sharing: Pragmatic Roadmaps for Pharmacoeconomic Practice W7: Preference Research in HTA Agencies Europe A Review of its Use in Approval, Reimbursement and Pricing P5: Access and Drug Use Studies P6: Modeling Studies 18:00-19:30 EXHIBITORS OPEN HOUSE RECEPTION & POSTERS 18:15-19:15 BREAKOUT SESSION 4 F1: Value of Information (VOI) Analysis for Research Decisions Emerging Good Practices Task Force: Final Recommendations F2: Towards a Value Framework for Precision Medicine: Recommendations from the ISPOR Precision Medicine Special Interest Group 5

6 F3: Market Access in Central and Eastern Europe: What Are the Drivers and Challenges? F4: Triangulating Developers, Regulators and Payers to Reap Rewards and Address Challenges with Curative Therapies F5: Does MCDA Lead to Better Patient Access in Africa? F6: Challenges in Medicines Funding For Rare Diseases 18:15-19:15 POSTER AUTHOR DISCUSSION HOUR Tuesday 13 November 7:30-8:30 EDUCATIONAL SYMPOSIUM Reducing Payer Uncertainty by Predicting Disease Outcomes and Identifying the Right Patient: Fact or Fantasy? (Sponsored by Takeda) 8:30-19:45 EXHIBIT & POSTER HALL HOURS 8:45-10:30 WELCOME & SECOND PLENARY SESSION Pharmaceutical Pricing: The Many Faces of Fairness 8:45-13:30 RESEARCH POSTER SESSION 3 10:30-11:00 BREAK, EXHIBITS & POSTERS 11:00-12:00 BREAKOUT SESSION 5 IP12: What Does Patient-Centered Care Mean for Medicine in the Welfare States of Europe? IP13: Digital Health vs. Patient Privacy (General Data Protection Regulation): Is the Future Here to Stay? IP14: Evaluating Medical Devices: How Does Randomized Clinical Trial Data and Real-World Data Fit Together? W8: Novel Approaches to Common Challenges in Modelling Of Survival Outcomes for Cost-Effectiveness Analyses in Oncology W9: How to Communicate Cost-Effectiveness Analysis to a Lay Audience? P7: Studies on Health Technology Assessment Agencies P8: Research on Methods 12:00-14:00 LUNCH, EXHIBITS & POSTERS 12:30-13:30 EDUCATIONAL SYMPOSIUM Roles of Biosimilars in Patient Access to Biologic Treatments (Sponsored by Celltrion Healthcare) 12:30-13:30 POSTER AUTHOR DISCUSSION HOUR 14:00-15:00 SPOTLIGHT SESSION 2 IP15: Transforming Healthcare: The Impact of Patient Engagement IP16: Valuing a Cure: Are New Approaches Needed? W10: Understanding and Addressing Potential Bias in Patient- Reported Outcomes from Clinical Trials 15:00-15:30 BREAK & EXHIBITS 15:30-16:30 BREAKOUT SESSION 6 IP17: US Value Frameworks vs. European and Commonwealth Priority Setting Frameworks: Is the US Offering Something Revolutionary or Reinventing the Wheel? IP18: Drug Disinvestment Is it Needed and How Could it Work? IP19: Structural Implementation of Patient Preferences in Health Technology Assessment: Will We Ever Get There? A Question Raised By IMI Prefer W11: Challenges and Lessons Learned From Electronic Recruitment and Validation of Patients for Outcome Research Studies in Rare Diseases W12: Are Missing Data Properly Accounted For in Health Economics and Outcomes Research? P9: Cancer Studies P10: Medical Device & Diagnostic Studies 15:30-19:00 RESEARCH POSTER SESSION 4 16:45-17:45 BREAKOUT SESSION 7 IP20: How Private Health Insurance Can Support the Implementation Of Universal Health Coverage in Emerging Economies? IP21: Access to Highly Specialized Treatments for Rare Conditions, What is the Role of Real World Evidence to Address HTA and Payer Uncertainty? W13: Economic Evaluation Transferability: A Comparative Examination of Assessing Medical Devices Across the EU in the Context of New HTA Proposal of the European Commission W14: Patient-Focused Drug Development and Patient-Centered Clinical Care: Working Together W15: Survival Extrapolation: How to Draw the Lines Beyond the Observed Data, If You Must P11: Cardiovascular Studies P12: Patient Preference Studies 17:45-19:15 EXHIBITORS RECEPTION 18:00-19:00 BREAKOUT SESSION 8 F7: What Can Health Economics Learn From Operations Research? F8: Health State Utility (HSU) Good Practices Task Force Recommendations for Identification and Use of HSU Data in Cost- Effectiveness in Decision Modeling F9: Diagnostics Evidentiary Dinosaur Evolution: Conventional Health Economics and Market Access Approaches vs. Advanced Analytics as the New Norm? F10: Priority Setting - Criteria and Process of Rare Diseases Management in CEE Countries F11: The ISPOR HEOR Competencies Framework : Guiding Professional Development for the Field of HEOR 18:00-19:00 POSTER AUTHOR DISCUSSION HOUR 20:30-23:30 ISPOR SOCIAL EVENT (separate registration required) Join us at the Museu Nacional d Art de Catalunya, the national museum of Catalan visual art for tours, dinner and dancing. Transportation will be provided. Wednesday 14 November 7:30-8:30 EDUCATIONAL SYMPOSIUM Advances in HEOR: New Frontiers Based on Developments in Artificial Intelligence (Sponsored by Analysis Group) 8:30-14:00 EXHIBIT & POSTER HALL HOURS 8:45-9:45 BREAKOUT SESSION 9 IP22: Are Single-Arm Clinical Trials Sufficient to Assess Value in Oncology and Rare Diseases? IP23: Can We Believe Their Beliefs: Is Expert Elicitation (Cost-) Effective? W16: What is Good for the Environment is Good for Healthcare How to Consider Green Sustainability in Value Assessments and Purchasing Decisions W17: Estimating Comparative Effectiveness in the Presence of Treatment Switching and Delayed Initiation (and Other Real-World Data Challenges!) 6 #ISPORBarcelona

7 P13: Adherence/Compliance Studies P14: Quality of Life Studies 8:45-13:15 RESEARCH POSTER SESSION 5 9:45-10:15 BREAK, EXHIBITS & RESEARCH POSTERS 10:15-11:45 WELCOME & THIRD PLENARY SESSION Budget Impact and Expenditure Caps: Potential or Pitfall? 11:45-13:45 LUNCH, EXHIBITS & RESEARCH POSTERS 12:15-13:15 POSTER AUTHOR DISCUSSION HOUR 13:45-14:45 BREAKOUT SESSION 10 IP24: Value of Diagnostic Information: How to Move from Concept to Reality of Evaluating and Measuring the Value of Diagnostic Information W18: Confounding by Indication - Current Practices and Future Applications W19: R You Seriously Still Using Excel? The Many Advantages of Open Source Decision Modeling in Efficient Programming Languages W20: When Do We Have Enough Evidence to Accept Migration of Patient-Reported Outcome Measures (PROMS) From Paper to Screen-Based Formats Without Additional Testing? P15: Diabetes Studies P16: Database Studies 15:00-16:00 BREAKOUT SESSION 11 IP25: Should Nutritional Products be Evaluated and Reimbursed the Same Way Pharmaceuticals Are? IP26: Will Regenerative Medicines Change the Way We Evaluate Evidence, Fund Innovation, and Determine Value? IP27: Addressing Challenges to Open Science: Data Sharing, Replication, and Robustness of Evidence from Real World Data W21: Indirect Treatment Comparisons: An Interactive Workshop on Choosing the Right Tool for the Available Data W22: Policy Measures to Maximize Patient Access after the Introduction of Biosimilar Medicines in the Off-Patent Biological Market P17: Neurological Disorders Studies CONFERENCE REGISTRATION FEES Early Registration Deadline: 25 September 2018 Through 25 September, 2018 After 25 September, 2018 Member Non-member Member Non-member Standard 900 ($1,113) 1,022 ($1,263) 1,000 ($1,238) 1,121 ($1,388) Clinical Practitioners (Clinical Practice, Hospital) 700 ($865) 821 ($958) 800 ($990) 921 ($1,140) Full-Time Government and Academia Member 600 ($742) 760 ($894) 700 ($865) 821 ($1,015) Patient Representative 250 ($309) 278 ($344) 350 ($433) 378 ($468) Full-Time Students 200 ($247) 228 ($282) 300 ($371) 328 ($406) 1 Day Registration (per day) Nov 12 Nov 13 Nov ($525) 546 ($675) 425 ($525) 546 ($675) CONFERENCE ENHANCEMENT FEES ISPOR Social Event: Tuesday, 20 November, 20:30-23:30 Museu Nacional d Art de Catalunya Member 90 ($111) Join us at the national museum of Catalan visual art for tours, dinner and dancing. Short course Continuing Education: Member 115 ($142) Register at All fees above reflect exchange rates as of April 2018 (1.24) Hotel/Venue Information: ISPOR Europe 2018 will be held at the Centre de Convencions Internacional de Barcelona, conveniently located close to public transportation for easy access by Aerobus and Metro. Learn more at public-transport/metro-airport Registration will be located in the Entrance Hall of the Centre de Convencions Internacional de Barcelona and posters and exhibits will be in Area 1-8. The K.I.T. Group has been appointed as the official and exclusive housing agent for ISPOR Europe Your hotel reservations will be part of the Conference block and K.I.T. Group will be available to provide support before and during the Conference. Attendees may reserve accommodations by visiting the Barcleona Hotel Information page on ISPOR s website or direct link: Accommodations are available on a first come, first served basis; subject to availability. Book now to secure your discounted rate. 7

8 ISPOR Europe 2018 The leading European conference for health economics and outcomes research New Perspectives for Improving 21st Century Health Systems Register by 25 September 2018 and SAVE! Discounted hotel rates until 22 August 2018, based on availability. ISPOR REIMAGINED 6 New Intriguing Short Courses! 3 Inspiring Plenary Sessions for Topics and Speakers! Opportunities to Meet Colleagues, Mingle and Network! Tailored Mobile App to Streamline Your ISPOR Barcelona Experience!